Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers

Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers

Bibliographic Details
Parent link:	Antiviral Research Vol. 158.— 2018.— [P. 147-160]
Corporate Author:	Национальный исследовательский Томский политехнический университет Исследовательская школа химических и биомедицинских технологий (ИШХБМТ)
Other Authors:	Brodskaya A. V. Aleksandra Vladimirovna, Timin A. S. Aleksandr Sergeevich, Gorshkov A. N. Andrey Nikolaevich, Muslimov A. N. Andrey Nikolaevich, Bondarenko A. B. Andrey Borisovich, Tarakanchikova Ya. V. Yana Vladimirovna, Zabrodskaya Ya. A. Yana Alekseevna, Iljinskaya E. V., Sakhenberg E. I. Elena Igorevna, Sukhorukov G. B. Gleb Borisovich, Vasin A. V.
Summary:	Title screen In the present study, a highly effective carrier system has been developed for the delivery of antiviral siRNA mixtures. The developed hybrid microcarriers, made of biodegradable polymers and SiO2 nanostructures, more efficiently mediate cellular uptake of siRNA than commercially available liposome-based reagents and polyethyleneimine (PEI); they also demonstrate low in vitro toxicity and protection of siRNA from RNase degradation. A series of siRNA designs (targeting the most conserved regions of three influenza A virus (IAV) genes: NP, NS, and PA) were screened in vitro using RT-qPCR, ELISA analysis, and hemagglutination assay. Based on the results of screening, the three most effective siRNAs (PA-1630, NP-717, and NS-777) were selected for in situ encapsulation into hybrid microcarriers. It was revealed that pre-treatment of cells with a mixture of PA-1630, NP-717, and NS-777 siRNAs, delivered by hybrid microcarriers, provided stronger inhibition of viral M1 mRNA expression and control of NP protein level, after viral infection, than single pre-treatment by any of three encapsulated siRNAs used in the study. Moreover, the effective inhibition of replication in several IAV subtypes (H1N1, H1N1pdm, H5N2, and H7N9) using a cocktail of the three selected siRNAs, delivered by our hybrid capsules to the cells, was achieved. In conclusion, we have developed a proof-of-principle which shows that our hybrid microcarrier technology (utilizing a therapeutic siRNA cocktail) may represent a promising approach in anti-influenza therapy. Режим доступа: по договору с организацией-держателем ресурса
Published:	2018
Subjects:	электронный ресурс труды учёных ТПУ siRNA delivery RNAi therapy influenza A virus hybrid microcontainers вирусы грипп терапия
Online Access:	https://doi.org/10.1016/j.antiviral.2018.08.003
Format:	Electronic Book Chapter
KOHA link:	https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=660145

Internet

https://doi.org/10.1016/j.antiviral.2018.08.003